Cell Therapy FCR001 to Enter Phase 1/2a Trial for Diffuse Cutaneous SSc

Talaris Therapeutics plans to initiate a Phase 1/2a trial to test its investigational cell therapy, FCR001, in people with diffuse cutaneous systemic sclerosis (dcSSc), the company has announced.

The trial follows the recent approval of an investigational new drug application for FCR001 by the U.S. Food and Drug Administration (FDA), and will be conducted across multiple sites in the U.S., including at Duke University and the University of Michigan. » FULL STORY

Health Care Heroes 2020

Members of the Louisville business community gathered Tuesday night to recognize and celebrate 31 health care professionals at Louisville Business First’s 2020 Health Care Heroes banquet.

Scott Requadt, CEO of Talaris Therapeutics Inc., headlined the event with a keynote address and question-and-answer session with LBF Editor Shea Van Hoy before a sell-out crowd of about 240 attendees at the Galt House.


Talaris CEO Scott Requadt speaking at the Louisville Healthcare Heroes 2020 event

Photo: Christopher Fryer/Louisville Business First